US › Healthcare

Neuraxis, Inc. (NRXS)

US · Healthcare · Biotechnology

$6.24+2.13%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$1.9M

Revenue YoY

+115.7%

Net profit

$-2.3M

EPS

$-0.19

EPS estimate

$-0.32

Net margin

-118.1%

EPS came in at -0.19 against a street estimate of -0.32 — a beat of 40.6%.

Key statistics

Market cap

$76.7M

Forward P/E

0.0

P/B

12.28

Book value

$0.54

EPS (TTM)

$-0.78

52-week high

$9.33

52-week low

$2.21

50-day MA

$6.87

200-day MA

$6.70

Beta

1.38

Analyst view

Analysts rate Neuraxis, Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

25.36%

Institutions

28.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neuraxis, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.